Allergan may have to buy a foreign company and complete a tax inversion if it wants to dodge a hostile takeover bid by Valeant Pharmaceuticals. But a recent attempt to bulk up didn't work out so well, <em>Reuters</em>' sources say.
written on 25.04.2014
Reuters: Allergan broached deal with Shire before Valeant's hostile bid
